Replies to post #1008 on Xenetic Biosciences Inc (XBIO)

[Kabuli]

This is just one reason for all the catalysts this company has under its belt.

As part of the Sublicense Agreement, Baxalta agreed to pay Xenetic a one-time payment of $7.5 million and single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.

Xenetic has previously received strategic investments from OPKO Health (Nasdaq:OPK), Serum Institute of India Limited and PJSC Pharmsynthez.